Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Notes Payables: 2014-2019

Historic Notes Payables for Ironwood Pharmaceuticals (IRWD) over the last 4 years, with Jun 2019 value amounting to $48.8 million.

  • Ironwood Pharmaceuticals' Notes Payables rose 96.28% to $48.8 million in Q2 2019 from the same period last year, while for Jun 2019 it was $48.8 million, marking a year-over-year increase of 96.28%. This contributed to the annual value of $47.6 million for FY2018, which is N/A change from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Notes Payables of $48.8 million as of Q2 2019, which was up 6.17% from $46.0 million recorded in Q1 2019.
  • In the past 5 years, Ironwood Pharmaceuticals' Notes Payables ranged from a high of $48.8 million in Q2 2019 and a low of $8.4 million during Q3 2016.
  • For the 2-year period, Ironwood Pharmaceuticals' Notes Payables averaged around $36.4 million, with its median value being $42.6 million (2018).
  • In the last 5 years, Ironwood Pharmaceuticals' Notes Payables plummeted by 58.23% in 2016 and then spiked by 284.35% in 2019.
  • Quarterly analysis of 4 years shows Ironwood Pharmaceuticals' Notes Payables stood at $25.0 million in 2015, then plummeted by 58.23% to $8.4 million in 2016, then reached $47.6 million in 2018, then skyrocketed by 96.28% to $48.8 million in 2019.
  • Its Notes Payables stands at $48.8 million for Q2 2019, versus $46.0 million for Q1 2019 and $47.6 million for Q4 2018.